Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Rockwell Medical (RMTI) EBIAT (2016 - 2026)

Rockwell Medical filings provide 16 years of EBIAT readings, the most recent being -$554000.0 for Q4 2025.

  • On a quarterly basis, EBIAT rose 26.72% to -$554000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.3 million, a 1007.08% decrease, with the full-year FY2025 number at -$5.3 million, down 1007.08% from a year prior.
  • EBIAT hit -$554000.0 in Q4 2025 for Rockwell Medical, up from -$1.8 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $1.7 million in Q3 2024 to a low of -$8.9 million in Q4 2021.
  • Median EBIAT over the past 5 years was -$1.8 million (2023), compared with a mean of -$3.3 million.
  • Biggest five-year swings in EBIAT: skyrocketed 188.89% in 2024 and later plummeted 534.99% in 2025.
  • Rockwell Medical's EBIAT stood at -$8.9 million in 2021, then soared by 73.58% to -$2.4 million in 2022, then surged by 35.99% to -$1.5 million in 2023, then soared by 50.0% to -$756000.0 in 2024, then increased by 26.72% to -$554000.0 in 2025.
  • The last three reported values for EBIAT were -$554000.0 (Q4 2025), -$1.8 million (Q3 2025), and -$1.5 million (Q2 2025) per Business Quant data.